Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

NEW YORK (GenomeWeb) – Myriad Genetics announced today it has expanded its collaboration with AstraZeneca and Merck to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer (mCRPC) and germline BRCA mutations who are likely to respond to olaparip (Lynparza).

Myriad said that depending on the success of the study, it intends to file a supplementary premarket approval application with the US Food and Drug Administration for use of BRACAnalysis CDx as a companion diagnostic for the drug for this specific patient population.

"There is a significant unmet medical need in men with metastatic, castration-resistant prostate cancer and BRCA1/2 mutations, which is an area where the utility of PARP inhibitors is being explored," Nicole Lambert, president of Myriad Oncology, said in a statement.  

The collaboration between Myriad and AstraZeneca started in 2007, and since then BRACAnalysis CDx has been approved by the FDA as a companion test for Lynparza in several ovarian and breast cancer indications.  

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.